# Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

> **NCT06195319** · PHASE1 · COMPLETED · sponsor: **Cassava Sciences, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Absorption
- Metabolism
- Excretion

## Interventions

- **DRUG:** Simufilam

## Key facts

- **NCT ID:** NCT06195319
- **Lead sponsor:** Cassava Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-07
- **Primary completion:** 2024-03-27
- **Final completion:** 2024-03-27
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06195319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06195319, "Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06195319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*